FRANKLIN LAKES, N.J., June 1, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today appointed John A. DeFord as executive vice president and chief technology officer. DeFord, 56, will report to Tom […]
Tag: BD
BD Announces Results For 2018 Second Fiscal Quarter; Raises Fiscal 2018 Guidance
FRANKLIN LAKES, N.J., May 3, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.222 billion for the second fiscal quarter ended March 31, 2018. This represents an increase of 42.2 percent from […]
BD Board Declares Dividends
FRANKLIN LAKES, N.J., April 23, 2018 /PRNewswire/ — The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.75 per common share, payable on June 29, 2018 to holders of record on June 8, 2018. The indicated annual dividend rate […]
BD Completes Asset Divestitures to Merit Medical
FRANKLIN LAKES, N.J., Feb. 15, 2018 /PRNewswire/ — Becton, Dickinson and Company (NYSE: BDX), a leading global medical technology company, announced today that it has completed the previously announced divestitures of its soft tissue core needle biopsy product line and Aspira® product line […]
BD Announces Completion of Enrollment in the Lutonix 014 Drug Coated Balloon Below-the-Knee Trial
FRANKLIN LAKES, N.J., Jan. 18, 2018 /PRNewswire/ — Becton, Dickinson and Company (NYSE: BDX), a leading global medical technology company, today announced the completion of enrollment in the Lutonix below-the-knee (BTK) trial and plans to submit a pre-market approval application in late […]
BD Statement On FTC Clearance Of Bard Acquisition
FRANKLIN LAKES, N.J., Dec. 22, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today’s clearance by the U.S. Federal Trade Commission (FTC) for BD to acquire C. R. Bard (NYSE: […]
BD Statement On European Commission Conditional Clearance Of Bard Acquisition
FRANKLIN LAKES, N.J., Oct. 18, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today’s clearance by the European Commission for BD to acquire C.R. Bard (NYSE: BCR), contingent on BD […]
C.R. Bard, Becton Dickinson Lead Australia Vascular Access Market due to New Technological Advancements
VANCOUVER, British Columbia, May 16, 2017 /PRNewswire/ — According to a new series of reports on the Australia vascular access device market by iData Research (www.idataresearch.com), peripheral intravenous catheters (PIVCs) and dialysis catheters represent the fastest growing segments in the vascular […]